Intuniv

For example, a newly FDA approved drug, "Intuniv" in an ad in September's "Clinical Psychiatry News," states, apparently proudly, that two clinical tests were run on this drug prior to FDA approval, one lasting six weeks, the other nine.

Ronald Ricker: Prescription Drugs: Why It's So Hard to Find Legit Psychiatric Medications Ronald Ricker 2010

Pharma also has to convince kids who grew diagnosed as ADHD not to quit their meds, says Mike Cola of Shire which makes the ADHD drugs Intuniv, Adderall XR, Vyvanse and the Daytrana patch.

Martha Rosenberg: 7 Diseases Big Pharma Hopes You Get in 2012 Martha Rosenberg 2011

Pharma also has to convince kids who grew diagnosed as ADHD not to quit their meds, says Mike Cola of Shire which makes the ADHD drugs Intuniv, Adderall XR, Vyvanse and the Daytrana patch.

Martha Rosenberg: 7 Diseases Big Pharma Hopes You Get in 2012 Martha Rosenberg 2011

Pharma also has to convince kids who grew diagnosed as ADHD not to quit their meds, says Mike Cola of Shire which makes the ADHD drugs Intuniv, Adderall XR, Vyvanse and the Daytrana patch.

Martha Rosenberg: 7 Diseases Big Pharma Hopes You Get in 2012 Martha Rosenberg 2011

Pharma also has to convince kids who grew diagnosed as ADHD not to quit their meds, says Mike Cola of Shire which makes the ADHD drugs Intuniv, Adderall XR, Vyvanse and the Daytrana patch.

Martha Rosenberg: 7 Diseases Big Pharma Hopes You Get in 2012 Martha Rosenberg 2011

Recently launched Intuniv and Vpriv also performed well, registering sales of $43 million and $59 million, respectively.

unknown title 2011

Some may develop severe insomnia from stimulant drugs and may be better off switching to a non-stimulant drug like Strattera or Intuniv.

Boston.com Top Stories 2011

So that's why the stimulants, which affect primarily norepinephrine, or some of the non-stimulant medications that are out there like Strattera or Intuniv, or there's an antidepressant called Wellbutrin, they primarily affect norepinephrine, so they have then some benefit for ADHD, but often not as much as the stimulants do.

A Mental Health Reader 2010

Irish drugmaker Shire PLC said Friday it filed a patent infringement lawsuit against Teva Pharmaceutical Industries Ltd., which is looking to sell a generic version of Shire's attention-deficit/hyperactivity drug Intuniv.

The Seattle Times 2010

Teva said it has requested Food and Drug Administration marketing approval for generic versions of extended-release Intuniv in doses of 1 to 4 milligram.

The Seattle Times 2010